Article Text

Download PDFPDF
CD147 in Ovarian and Other Cancers
  1. Hong Yang, PhD and
  2. Biliang Chen, PhD
  1. Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University, Xi’an, China.
  1. Address correspondence and reprint requests to Hong Yang, PhD, Department of Obstetrics and Gynecology, Xijing Hospital, Fourth Military Medical University, No. 15, Changle Rd, Xincheng District, Xi’an 710032, China. E-mail: yanghong{at}


Ovarian cancer, a gynecological malignancy, is the most common cause of death in older women worldwide. The overall 5-year survival of ovarian cancer patients is only 20% because of late diagnosis, as well as distant metastasis and multidrug resistance. Therefore, predictive and prognostic markers are urgently required for the early diagnosis of ovarian cancer. CD147, an extracellular matrix metalloproteinase inducer, is overexpressed in ovarian cancers. Current knowledge suggests that CD147 is associated with the survival and progression of ovarian cancer, and is considered as a biomarker of poor outcome. Here, we specifically review the roles of CD147 in ovarian cancer progression and discuss the diagnostic and prognostic value of CD147 in patients with ovarian cancer. CD147 promotes ovarian cancer progression by its involvement in every facet of malignancy, including invasion, metastasis, survival, angiogenesis, and drug resistance. Although it is not fully confirmed, the combination of CD147 with other biomarkers might be of diagnostic value.

  • CD147
  • Ovarian cancer
  • Matrix metalloproteinases
  • Metastasis
  • Drug resistance

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Supported by the National Natural Science Foundation of China Grants 30772305 and 81072144.

  • The authors declare no conflicts of interest.